Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -65.55% is in line with its 5-year average of -62.32%, around the middle of its 5-year range (-140.06%–-23.17%).
23.81% above its 12-month average of -86.04%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -129.13%.
EBITDA MARGIN
-65.55%
EBITDA MARGIN AVG TTM
-86.04%
EBITDA MARGIN AVG 3Y
-57.35%
EBITDA MARGIN AVG 5Y
-62.32%
EBITDA MARGIN AVG 10Y
-73.42%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+23.81%
CURRENT VS 3Y AVG
-14.30%
CURRENT VS 5Y AVG
-5.19%
CURRENT VS 10Y AVG
+10.72%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Quanterix Corporation
Market Cap
$163.22M
EBITDA Margin
-65.55%
TTM Avg
-86.04%
3Y Avg
-57.35%
5Y Avg
-62.32%
Market Cap
$161.45M
EBITDA Margin
-416.41%
TTM Avg
-228.13%
3Y Avg
-163.44%
5Y Avg
-116.60%
Market Cap
$165.70M
EBITDA Margin
14.98%
TTM Avg
2.40%
3Y Avg
-11.30%
5Y Avg
-6.96%
Market Cap
$165.56M
EBITDA Margin
-18889.15%
TTM Avg
-9445.90%
3Y Avg
-9445.90%
5Y Avg
-9445.90%
Market Cap
$159.80M
EBITDA Margin
4.91%
TTM Avg
4.91%
3Y Avg
4.91%
5Y Avg
4.91%
Market Cap
$169.21M
EBITDA Margin
14.71%
TTM Avg
8.99%
3Y Avg
8.81%
5Y Avg
10.76%
Market Cap
$169.17M
EBITDA Margin
-138.09%
TTM Avg
-113.30%
3Y Avg
-81.67%
5Y Avg
-67.39%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quanterix Corporation (QTRX) | $163.22M | -65.55% | -86.04% | -57.35% | -62.32% |
| Coherus Oncology, Inc. (CHRS)vs › | $161.45M | -416.41% | -228.13% | -163.44% | -116.60% |
| OptimizeRx Corp. (OPRX)vs › | $165.70M | 14.98% | 2.40% | -11.30% | -6.96% |
| Nkarta, Inc. (NKTX)vs › | $165.56M | -18889.15% | -9445.90% | -9445.90% | -9445.90% |
| Minerva Neurosciences, Inc. (NERV)vs › | $159.80M | 4.91% | 4.91% | 4.91% | 4.91% |
| PepGen Inc. (PEPG)vs › | $159.44M | N/A | N/A | N/A | N/A |
| Organogenesis Holdings Inc. (ORGO)vs › | $169.21M | 14.71% | 8.99% | 8.81% | 10.76% |
| Inogen, Inc. (INGN)vs › | $156.90M | -2.74% | -4.58% | -13.60% | -7.28% |
| MediWound Ltd. (MDWD)vs › | $169.17M | -138.09% | -113.30% | -81.67% | -67.39% |
| Cue Biopharma, Inc. (CUE)vs › | $169.84M | -83.89% | -252.72% | -1380.70% | -1383.45% |
Gross Margin
42.6%
EBITDA Margin
-65.5%
Operating Margin
-86.2%
Net Margin
-80.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -129.13% |
| 2026-03-31 | -41.54% |
| 2025-12-31 | -37.90% |
| 2025-09-30 | -81.55% |
| 2025-06-30 | -140.06% |
| 2025-03-31 | -79.87% |
| 2024-12-31 | -32.70% |
| 2024-09-30 | -30.98% |
| 2024-06-30 | -24.91% |
| 2024-03-31 | -42.89% |
| 2023-12-31 | -42.82% |
| 2023-09-30 | -38.03% |
| 2023-06-30 | -23.17% |
| 2023-03-31 | -28.27% |
| 2022-12-31 | -81.18% |
| 2022-09-30 | -137.05% |
| 2022-06-30 | -96.49% |
| 2022-03-31 | -56.95% |
| 2021-12-31 | -61.45% |
| 2021-09-30 | -52.51% |
| 2021-06-30 | -49.17% |
| 2021-03-31 | -31.75% |
| 2020-12-31 | -33.71% |
| 2020-09-30 | 11.49% |
| 2020-06-30 | -85.06% |
| 2020-03-31 | -67.92% |
| 2019-12-31 | -67.00% |
| 2019-09-30 | -60.28% |
| 2019-06-30 | -73.66% |
| 2019-03-31 | -72.53% |
| 2018-12-31 | -83.49% |
| 2018-09-30 | -68.46% |
| 2018-06-30 | -80.69% |
| 2018-03-31 | -137.44% |
| 2017-12-31 | -105.45% |
| 2017-09-30 | -109.26% |
| 2017-06-30 | -121.96% |
| 2017-03-31 | -111.50% |
| 2016-12-31 | -100.31% |
| 2016-09-30 | -148.30% |
| 2016-06-30 | -154.47% |
| 2016-03-31 | -103.50% |
